Danaher Co. (NYSE:DHR) Stock Holdings Reduced by Plimoth Trust Co. LLC

Plimoth Trust Co. LLC trimmed its position in shares of Danaher Co. (NYSE:DHR) by 8.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,778 shares of the conglomerate’s stock after selling 170 shares during the quarter. Plimoth Trust Co. LLC’s holdings in Danaher were worth $444,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Cape Investment Advisory Inc. bought a new stake in Danaher in the fourth quarter worth approximately $25,000. Tsfg LLC lifted its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. BKM Wealth Management LLC acquired a new stake in shares of Danaher in the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher in the fourth quarter worth $29,000. Finally, Rakuten Securities Inc. acquired a new position in Danaher during the fourth quarter worth $36,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several recent analyst reports. Barclays upped their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Citigroup upped their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Bank of America lifted their price target on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Robert W. Baird upped their price objective on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Finally, TD Cowen lifted their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $268.67.

Danaher Stock Performance

NYSE DHR opened at $240.21 on Thursday. The firm has a market cap of $177.92 billion, a price-to-earnings ratio of 40.71, a PEG ratio of 3.82 and a beta of 0.84. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11. The company has a 50 day moving average of $255.88 and a 200-day moving average of $246.95.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue was down 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.36 earnings per share. On average, equities analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s payout ratio is currently 18.31%.

Insider Activity

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Insiders have sold 148,783 shares of company stock valued at $37,536,717 over the last 90 days. 10.90% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.